Article

Daily Medication Pearl: Voriconazole (Vfend)

Voriconazole (Vfend) is an azole antifungal indicated for the treatment of invasive aspergillosis and Candidemia in non-neutropenics and other deep tissue Candida infections.

Medication Pearl of the Day: Voriconazole (Vfend)

Indication: Voriconazole (Vfend) is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with invasive aspergillosis and Candidemia in non-neutropenics and other deep tissue Candida infections.

Insight:

  • Dosing: May start from 4 mg/kg/day and extend to 9 mg/kg/day based on the patient.
  • Dosage forms: Tablets 50 mg, 200 mg.
  • Adverse events: The most common adverse reactions (incidence ≥2%) were visual disturbances, fever, nausea, rash, vomiting, chills, headache, liver function test abnormal, tachycardia, and hallucinations.
  • Mechanism of action: Voriconazole is an antifungal drug.

Source:

https://labeling.pfizer.com/showlabeling.aspx?id=618

Related Videos
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Pharmacists working in a pharmacy -- Image credit: Drazen | stock.adobe.com
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC
Bacteria of clostridioides difficile infection -- Image credit: Artur | stock.adobe.com
Pharmacy School, social media, non-traditional learning | Image Credit: Ахтем - stock.adobe.com
Pharmacy, Community, Health Care, Health System | Image Credit: StratfordProductions - stock.adobe.com